Datamonitor Healthcare interviewed three KOLs on ovarian cancer, one based each in the US, France, and Italy. The topics discussed include clinical and commercial advantages and disadvantages of marketed and late-stage pipeline drugs, pricing, market access and reimbursement issues, and optimum clinical trial design for the indication. The three interviews were combined into a single report.

If you are a KOL Insight Subscriber, please access the first, second, and third interviews from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.